Ethnic differences in cardiovascular drug response potential contribution of pharmacogenetics

被引：159

作者：

Johnson, Julie A. ^{[1
,2
,3
]}

机构：

[1] Univ Florida, Ctr Pharmacogenom, Dept Pharm Practice, Gainesville, FL 32610 USA

[2] Univ Florida, Ctr Pharmacogenom, Dept Pharmaceut, Gainesville, FL 32610 USA

[3] Univ Florida, Ctr Pharmacogenom, Dept Med, Gainesville, FL 32610 USA

来源：

CIRCULATION | 2008年 / 118卷 / 13期

基金：

美国国家卫生研究院;

关键词：

hypertension; heart failure; anticoagulants; pharmacogenetics; ethnicity;

D O I：

10.1161/CIRCULATIONAHA.107.704023

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1383 / 1393

页数：11

共 69 条

[1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[2] Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation [J].

Anderson, Jeffrey L. ;

Horne, Benjamin D. ;

Stevens, Scott M. ;

Grove, Amanda S. ;

Barton, Stephanie ;

Nicholas, Zachery P. ;

Kahn, Samera F. S. ;

May, Heidi T. ;

Samuelson, Kent M. ;

Muhlestein, Joseph B. ;

Carlquist, John F. .

CIRCULATION, 2007, 116 (22) :2563-2570

[3]

[Anonymous], 1988, ARCH INTERN MED, V148, P1023

[4] The pharmacology and management of the vitamin K antagonists [J].

Ansell, J ;

Hirsh, J ;

Poller, L ;

Bussey, H ;

Jacobson, A ;

Hylek, E .

CHEST, 2004, 126 (03) :204S-233S

[5] Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements [J].

Aquilante, CL ;

Langaee, TY ;

Lopez, LM ;

Yarandi, HN ;

Tromberg, JS ;

Mohuczy, D ;

Gaston, KL ;

Waddell, CD ;

Chirico, MJ ;

Johnson, JA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) :291-302

[6] Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment - The genetics of hypertension-associated treatment (GenHAT) study [J].

Arnett, DK ;

Davis, BR ;

Ford, CE ;

Boerwinkle, E ;

Leiendecker-Foster, C ;

Miller, MB ;

Black, H ;

Eckfeldt, JH .

CIRCULATION, 2005, 111 (25) :3374-3383

[7] Systematic review: Antihypertensive drug therapy in black patients [J].

Brewster, LM ;

van Montfrans, GA ;

Kleijnen, J .

ANNALS OF INTERNAL MEDICINE, 2004, 141 (08) :614-627

[8] Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-blocker evaluation of survival trial [J].

Bristow, MR ;

Krause-Steinrauf, H ;

Nuzzo, R ;

Liang, CS ;

Lindenfeld, J ;

Lowes, BD ;

Hattler, B ;

Abraham, WT ;

Olson, L ;

Krueger, S ;

Thaneemit-Chen, S ;

Hare, JM ;

Loeb, HS ;

Domanski, MJ ;

Eichhorn, EJ ;

Zelis, R ;

Lavori, P .

CIRCULATION, 2004, 110 (11) :1437-1442

[9]

BRISTOW MR, 2005, CIRCULATION S2, V112, P351

[10] Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] study) [J].

Brunner, Martin ;

Cooper-DeHoff, Rhonda M. ;

Gong, Yan ;

Karnes, Jason H. ;

Langaee, Tairnour Y. ;

Pepine, Carl J. ;

Johnson, Julie A. .

AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (11) :1549-1554

← 1 2 3 4 5 6 7 →